Provider alert

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Blue Cross commercial and BCN commercial Category: Authorizations/referrals, Pharmacy

Date posted: Aug. 29, 2022

Skyrizi[®] IV to have site-of-care requirement for most commercial members starting Dec. 1

For dates of service on or after Dec. 1, 2022, we're adding a site-of-care requirement for Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members for the following drug covered under the medical benefit:

Skyrizi intravenous (risankizumab-rzaa), HCPCS code J3590

You'll be prompted to select a site of care when you submit prior authorization requests for Skyrizi IV.

If the member meets clinical criteria for the drug, requests for the following sites of care will be approved automatically:

- · Doctor's or other health care provider's office
- Ambulatory infusion center
- The member's home, from a home infusion therapy provider

Additional information or documentation may be required for requests to administer Skyrizi IV in an outpatient hospital setting.

As a reminder, this drug already requires prior authorization; providers can submit prior authorization requests using the NovoLogix[®] online tool. The new site-of-care requirement is in addition to the current prior authorization requirement.

Members who start courses of treatment with Skyrizi IV before Dec. 1, 2022, will be able to continue receiving the drug in their current location until their existing authorization expires. If those members then continue treatment under a new prior authorization, the site-of-care requirements outlined above will apply.

Reminder: Skyrizi SC is covered under the pharmacy benefit

Skyrizi[®] SC (risankizumab-rzaa), HCPCS code J3590, isn't covered under members' medical benefits. Subcutaneous injections are self-administered and are covered under members' pharmacy benefits.

Some Blue Cross commercial groups not subject to these requirements

For Blue Cross commercial groups, this authorization requirement applies only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list.

Provider alert



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Blue Cross commercial and BCN commercial Category: Authorizations/referrals, Pharmacy

Date posted: Aug. 29, 2022

Note: Blue Cross and Blue Shield Federal Employee Program[®] members and UAW Retiree Medical Benefits Trust (non-Medicare) members don't participate in the standard prior authorization program.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the <u>Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members</u>. We'll update this list prior to Dec. 1.

You can access this list and other information about requesting prior authorization at **ereferrals.bcbsm.com**, at these locations:

- <u>Blue Cross Medical Benefit Drugs</u> page
- BCN Medical Benefit Drugs page

Authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.